Baseline CD4 count and adherence to antiretroviral therapy: A systematic review and meta-analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 73, Issue 5, 2016, Pages 514-521

  Bock, Peter ^a   James, Anelet ^a   Nikuze, Alliance ^b   Peton, Neshaan ^c   Sabapathy, Kalpana ^d   Mills, Edward ^e   Fidler, Sarah ^f   Ford, Nathan ^f,g  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b Independent consultant   (South Africa)

^c WESTERN CAPE DEPARTMENT OF AGRICULTURE   (South Africa)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e Department of Health Analytics   (Canada)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

adherence; antiretroviral therapy; CD4 count; HIV

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIRETROVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; ENGLISH (LANGUAGE); HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; META ANALYSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WEB OF SCIENCE; IMMUNOLOGY; MEDICATION COMPLIANCE; PATHOLOGY;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84996993128     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001092     Document Type: Review

References (54)

1. UNAIDS. Global AIDS Update 2016. Geneva, Switzerland: UNAIDS; 2016
2. Gupta S, Granich R, Suthar AB, et al. Global policy review of antiretroviral therapy eligibility criteria for treatment and prevention of HIV and tuberculosis in adults, pregnant women, and serodiscordant couples. J Acquir Immune Defic Syndr. 2013; 62: e87-e97
3. World Health Organisation. Consolidated Guidelines for the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Reccomendations for a Public Health Approach. Geneva, Switzerland: World Health Organisation; 2013
4. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early Asymptomatic HIV infection. N Engl J Med. 2015; 373: 795-807
5. Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and Isoniazid preventive therapy in Africa. N Engl J Med. 2015; 373: 808-822
6. World Health Organization. Guideline on When to Start Antiretroviral Therapy and on Pre-exposure Prophylaxis for HIV. Geneva, Switzerland: World Health Organization; 2015
7. UNAIDS. 90-90-90-An Ambitious Treatment Target to Help End the AIDS Epidemic. Geneva, Switzerland: UNAIDS; 2014. http://www. unaids.org/en/resources/documents/2014/90-90-90
8. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296: 679-690
9. Goldman JD, Cantrell RA, Mulenga LB, et al. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses. 2008; 24: 1031-1035
10. Glass TR, Rotger M, Telenti A, et al. Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. PLoS One. 2012; 7: e29186
11. Lockman S, Sax P. Treatment-for-prevention: Clinical considerations. Curr Opin HIV AIDS. 2012; 7: 131-139
12. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS. 2010; 24: 2263-2270
13. Hodgson I, Plummer ML, Konopka SN, et al. A systematic review of individual and contextual factors affecting ART initiation, adherence, and retention for HIV-infected pregnant and postpartum women. PLoS One. 2014; 9: e111421
14. Fidler S, Bock P. Prophylactic antiretroviral HIV therapy prevents infection in heterosexual men and women. Evid Based Med. 2013; 18: 184-185
15. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4: 1
16. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336: 924-926
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7: 177-188
18. Mills EJ, Jansen JP, Kanters S. Heterogeneity in meta-analysis of FDGPET studies to diagnose lung cancer. JAMA. 2015; 313: 419
19. The World Bank. Country and Lending Groups. Washington DC; 2016
20. Abaasa AM, Todd J, Ekoru K, et al. Good adherence to HAART and improved survival in a community HIV/AIDS treatment and care programme: the experience of the AIDS Support Organization (TASO), Kampala, Uganda. BMC Health Serv Res. 2008; 8: 241
21. Bonolo Pde F, Cesar CC, Acurcio FA, et al. Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil. AIDS. 2005; 19(suppl 4): S5-S13
22. Byakika-Tusiime J, Polley EC, Oyugi JH, et al. Free HIV antiretroviral therapy enhances adherence among individuals on stable treatment: implications for potential shortfalls in free antiretroviral therapy. PLoS One. 2013; 8: e70375
23. Carrieri MP, Leport C, Protopopescu C, et al. Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr. 2006; 41: 477-485
24. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: a longitudinal analysis for risk factors. PLoS One. 2010; 5: e10584
25. Chi BH, Cantrell RA, Zulu I, et al. Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. Int J Epidemiol. 2009; 38: 746-756
26. Conen A, Wang Q, Glass TR, et al. Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study. J Acquir Immune Defic Syndr. 2013; 64: 472-478
27. Denison JA, Koole O, Tsui S, et al. Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia. AIDS. 2015; 29: 361-371
28. Diabate S, Alary M, Koffi CK. Determinants of adherence to highly active antiretroviral therapy among HIV-1-infected patients in Cote d?Ivoire. AIDS. 2007; 21: 1799-1803
29. Elul B, Basinga P, Nuwagaba-Biribonwoha H, et al. High levels of adherence and viral suppression in a nationally representative sample of HIV-infected adults on antiretroviral therapy for 6, 12 and 18 months in Rwanda. PLoS One. 2013; 8: e53586
30. Gare J, Kelly-Hanku A, Ryan CE, et al. Factors influencing antiretroviral adherence and virological outcomes in people living with HIV in the Highlands of Papua New Guinea. PLoS One. 2015; 10: e0134918
31. Kyser M, Buchacz K, Bush TJ, et al. Factors associated with nonadherence to antiretroviral therapy in the SUN study. AIDS Care. 2011; 23: 601-611
32. Lima VD, Reuter A, Harrigan PR, et al. Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes. AIDS. 2015; 29: 1871-1882
33. Maqutu D, Zewotir T, North D, et al. Factors affecting first-month adherence to antiretroviral therapy among HIV-positive adults in South Africa. Afr J AIDS Res. 2010; 9: 117-124
34. Maqutu D, Zewotir T, North D, et al. Determinants of optimal adherence over time to antiretroviral therapy amongst HIV positive adults in South Africa: a longitudinal study. AIDS Behav. 2011; 15: 1465-1474
35. Memiah P, Shumba C, Etienne-Mesubi M, et al. The effect of depressive symptoms and CD4 count on adherence to highly active antiretroviral therapy in sub-Saharan Africa. J Int Assoc Provid AIDS Care. 2013; 13: 346-352
36. Merlin JS, Westfall AO, Raper JL, et al. Pain, mood, and substance abuse in HIV: implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure. J Acquir Immune Defic Syndr. 2012; 61: 164-170
37. Moore DM, Zhang W, Yip B, et al. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme. HIV Med. 2010; 11: 299-307
38. Murphy K, Hoover DR, Shi Q, et al. Association of self-reported race with AIDS death in continuous HAART users in a cohort of HIV-infected women in the United States. AIDS. 2013; 27: 2413-2423
39. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006; 84: 188-194
40. Pefura-Yone EW, Soh E, Kengne AP, et al. Non-adherence to antiretroviral therapy in Yaounde: prevalence, determinants and the concordance of two screening criteria. J Infect Public Health. 2013; 6: 307-315
41. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007; 45: 1492-1498
42. Rougemont M, Stoll BE, Elia N, et al. Antiretroviral treatment adherence and its determinants in sub-Saharan Africa: a prospective study at Yaounde Central hospital, Cameroon. AIDS Res Ther. 2009; 6: 21
43. Saha R, Saha I, Sarkar AP, et al. Adherence to highly active antiretroviral therapy in a tertiary care hospital in West Bengal, India. Singapore Med J. 2014; 55: 92-98
44. Sarna A, Pujari S, Sengar AK, et al. Adherence to antiretroviral therapy & its determinants amongst HIV patients in India. Indian J Med Res. 2008; 127: 28-36
45. Shannon K, Kerr T, Lai C, et al. Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use. J Int Assoc Physicians AIDS Care (Chic). 2005; 4: 66-72
46. Weiser SD, Palar K, Frongillo EA, et al. Longitudinal assessment of associations between food insecurity, antiretroviral adherence and HIV treatment outcomes in rural Uganda. AIDS. 2014; 28: 115-120
47. Deloria-Knoll M, Chmiel JS, Moorman AC, et al. Factors related to and consequences of adherence to antiretroviral therapy in an ambulatory HIV-infected patient cohort. AIDS Patient Care STDs. 2004; 18: 721-727
48. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, et al. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet. 2009; 374: 921-933
49. Bemelmans M, Baert S, Goemaere E, et al. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. 2014; 19: 968-977
50. Langebeek N, Gisolf EH, Reiss P, et al. Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. BMC Med. 2014; 12: 142
51. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Med. 2006; 3: e438
52. Saberi P, Neilands TB, Vittinghoff E, et al. Barriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participants. AIDS Patient Care STDs. 2015; 29: 111-116
53. Nachega JB, Parienti JJ, Uthman OA, et al. Lower pill burden and oncedaily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014; 58: 1297-1307
54. Bijker J, Jiamsakul A, Siwale M, et al. Determinants of adherence to antiretroviral therapy differ between Africa and Asia. Conference on Retroviruses and Opportunistic Infections (CROI), February 23-26, 2015; Seattle, WA.